Company statement regarding the prevention of Modern Slavery
For the year ending 31 December 2025
1. Introduction
Meribel Pharma Solutions is a major player in pharmaceutical development and manufacturing, operating in Sweden, France, Spain and the UK, and supplying medicines worldwide.
Our vision: To achieve exceptional service, continuously raising standards to new heights and contributing to positive change in worldwide healthcare for generations to come.
Our mission: To consistently deliver the highest quality solutions and service, enabling customers to scale new heights and improve patient health.
We are committed to complying with the highest standards of regulatory compliance, business ethics, and social responsibility. Our Code of Conduct is available at https://meribelpharma.com/code-of-conduct.
2. Our approach to the prevention of Modern Slavery
Meribel Pharma Solutions (the trading name for our operating parent company, BW CDMO Holdings UK Limited) issues this statement on behalf of itself and each of its subsidiaries, as listed in Schedule 1 (together « Meribel Pharma »).
Meribel Pharma is committed to acting ethically and with integrity. In line with our Code of Conduct, we are committed to ensuring that we operate our business with an unwavering respect for human rights and in compliance with all applicable laws and regulations.
Our Code of Conduct, and in particular our Employee/Human Rights and Social Responsibility policy (Annex 6 of our Code of Conduct), demonstrate our commitment to guaranteeing a safe and respectful work environment, and upholding human rights, including:
– Prohibition of modern slavery, forced labor and child labor in our organisation and
throughout our global supply chain.
– Promotion of diversity, inclusion, and equal opportunities.
– Compliance with occupational health and safety standards.
All employees receive compulsory annual training on the importance of acting ethically and with integrity in every area of our business, including being vigilant for any potential compliance issues by our partners and in our supply chain. We encourage a regular dialogue by all employees with the Group’s Legal department and/or their use of the Meribel Pharma independent whistleblowing hotline.
This hotline is available to all employees and partners to raise any concerns they may have, anonymously if requested, including those related to human rights issues. All reports are investigated by suitably qualified and independent experts, external if necessary.
Our partners are also expected to comply with our Code of Conduct, including in relation to the prevention of modern slavery and human trafficking, and compliance with all applicable laws and regulations. We expect them to not only comply and train their staff, but to demand the same from each of their partners.
Our employees and our partners are committed to the Code of Conduct and to ensuring that our supply chain is vetted and compliant, even though it is a complex international supply chain.
We operate a ‘zero tolerance’ approach to any infringement of modern slavery and human trafficking in our supply chain.
We have created a process to conduct detailed due diligence and risk assessments of our partners as part of our commitment to this topic.
We consider that this is a continuous improvement project and we regularly assess our practices compared to best practices, and any areas we can improve our compliance processes.
In this way, we show our respect for the human rights and dignity of all people globally. This, and our work in developing and manufacturing healthcare products, show our continuing commitment to improving the quality of life of all people globally.
Bruce Vielle
CEO, Meribel Pharma Solutions